Florian Rader, ACC 2022: Interim results of the MAVA-LTE study of mavacamten in the treatment of symptomatic obstructive hypertrophic cardiomyopathy

In the MAVA-LTE and EXPLORER LTE studies, mavacamten is predicted to reduce left ventricular outflow tract obstruction and potentially reduce heart thickening in patients with symptomatic obstructive hypertrophic cardiomyopathy. touchCARDIO spoke to Dr Florian Rader (Cedars-Sinai Medical Center, Los Angeles, CA, USA) to discusses the interim results of the MAVA-LTE study and the clinical implications of the results of the EXPLORER LTE study.

The presentation entitled: ‘Updated Cumulative Results of Treatment With Mavacamten From the EXPLORER-LTE Cohort of the MAVA-LTE Study in Patients With Obstructive Hypertrophic Cardiomyopathy’ was presented at the the American College of Cardiology Annual Meeting 2022.

Questions

1.       What is the mechanism of action of mavacamten and what is the rationale for its use in obstructive hypertrophic cardiomyopathy?  00:15-01:58
2.       What are the aims and design of the MAVA-LTE study? 01:58-03:16
3.       What have been the overall findings of the study to date? 03:16-06:36
4. Could you tell us a little about the EXPLORER LTE study and the effect of mavacamten in this cohort? 06:46-07:48
5. What are the clinical implications of these findings? 07:48-09:06

Speaker Disclosure: Florian Radar is a consultant for Medtronic, a member of the Advisory Board for Medtronic and ReCor and a Speaker’s Bureau participant for Medtronic and Bristol Myers Squibb.

Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Sophie Nickelson.

Filmed in coverage of the American College of Cardiology Annual Meeting 2022